Product Description: Fosfomycin (MK-0955) sodium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin sodium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria[1][2].
Applications: COVID-19-immunoregulation
Formula: C3H5Na2O4P
Citations: Antibiotics (Basel). 2021 Sep 14;10(9):1110./bioRxiv. 2024 May 10./Nat Commun. 2022 Mar 2;13(1):1116./Front Cell Infect Microbiol. 2019 Jul 15;9:253./J Med Microbiol. 2019 Mar;68(3):493-502.
References: [1]Dijkmans AC, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel). 2017 Oct 31. 6(4):24. /[2]Inouye S, et al. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J Pharmacobiodyn. 1982 Sep. 5(9):659-69./[3]Inouye S, et al. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. J Pharmacobiodyn. 1982 Dec. 5(12):941-50./[4]Falagas ME, et al. Fosfomycin. Clin Microbiol Rev. 2016 Apr. 29(2):321-47.
CAS Number: 26016-99-9
Molecular Weight: 182.02
Compound Purity: 98.0
Research Area: Infection; Cancer
Solubility: H2O : 125 mg/mL (ultrasonic)
Target: Antibiotic;Bacterial
English
Deutsch
